CD200:CD200R-Mediated Regulation of Immunity

Table 1

CD200^tg, CD200R1KO, and CD200R1KO·CD200^tg graft survival in wt/CD200^tg mice.

BL/6 donor mice^a	BALB/c recipients^b	MST (with range)^c	Percentage of grafts surviving >75 d
Control (wt)	wt	9.4 (7–12)	0%
Control (wt)	CD200^tg	48.8 (19–129)**	50%
CD200KO	wt	7.6 (7–11)	0%
CD200KO	CD200^tg	42.2 (15–121)**	40%
CD200R1KO	wt	8.8 (7–13)	0%
CD200R1KO	CD200^tg	32.4 (17–88)*	20%
CD200R1KO·CD200^tg	wt	11 (9–25)	0%
CD200R1KO·CD200^tg	CD200^tg	33 (19–97)*	30%

a,bCardiac grafts were obtained from individual donors (all on doxycycline, DOX, for 7 days to induce transgene expression) and transplanted to 10 recipients/group (all maintained on DOX).
^cGrafts were palpated daily for evidence of rejection; MST indicates mean (graft) survival time in days. *𝑃<0.05 compared with 1st row; **𝑃<0.05 compared with CD200R1KO or CD200R1KO·CD200^tg grafts transplanted to CD200^tg (rows 6 and 8).